BPC-157 in Cardiovascular Research: Research Applications Guide 2026
This comprehensive, evidence-based guide examines the latest published research on BPC-157 cardiovascular research, providing researchers with an in-depth analysis of molecular mechanisms, preclinical findings, clinical trial data, and practical implications for laboratory investigation. With the peptide research landscape evolving rapidly, staying current on BPC-157 cardiovascular research has become essential for investigators designing rigorous experimental protocols.
Over the past decade, research into BPC-157 cardiovascular research has produced a substantial body of peer-reviewed evidence, spanning hundreds of published studies across leading scientific journals. This guide synthesizes the most impactful findings, highlights critical knowledge gaps, and identifies emerging research directions that are reshaping the field.
Whether you are an experienced peptide researcher or exploring this domain for the first time, this guide provides the scientific context needed to evaluate published evidence and design informed experiments. For high-purity research compounds, explore our complete selection of research peptides with third-party testing and Certificates of Analysis.
Table of Contents
- In Vitro Research Findings
- Emerging Applications and Future Directions
- Preclinical Evidence: Key Animal Studies
- Clinical Trial Evidence and Human Data
- Structure-Activity Relationships
- Molecular Mechanisms and Cellular Signaling
- Biomarker Analysis and Outcome Measures
- Genomic and Transcriptomic Evidence
- Combination Research and Synergistic Effects
- Dose-Response Data and Optimal Concentrations
- Safety and Tolerability in Published Research
- Pharmacokinetic Profile and Bioavailability
- FAQ
- Shop Peptides
In Vitro Research Findings
Understanding in vitro research findings is fundamental to comprehensive BPC-157 cardiovascular research investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Longitudinal research tracking BPC-157 cardiovascular research effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
Related research compounds include Semaglutide and Ipamorelin, available with purity documentation from Proxiva Labs.
These findings demonstrate the multifaceted nature of BPC-157 cardiovascular research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Huo et al., 2016, establishing critical parameters for understanding these mechanisms.
Emerging Applications and Future Directions
Research into emerging applications and future directions has generated substantial evidence illuminating how BPC-157 cardiovascular research interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to BPC-157 cardiovascular research. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
For laboratory work, BPC-157 are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Munoz-Espin et al., 2014, establishing critical parameters for understanding these mechanisms.
Preclinical Evidence: Key Animal Studies
The scientific literature on preclinical evidence: key animal studies provides critical insights into BPC-157 cardiovascular research research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Studies examining BPC-157 cardiovascular research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
For laboratory work, BPC-157 are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The cumulative evidence provides a solid foundation for continued BPC-157 cardiovascular research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Saxton & Sabatini, 2017, establishing critical parameters for understanding these mechanisms.
Clinical Trial Evidence and Human Data
Understanding clinical trial evidence and human data is fundamental to comprehensive BPC-157 cardiovascular research investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Studies examining BPC-157 cardiovascular research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
For laboratory work, BPC-157 are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
These findings demonstrate the multifaceted nature of BPC-157 cardiovascular research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Anisimov et al., 2003, establishing critical parameters for understanding these mechanisms.
Structure-Activity Relationships
Investigation of structure-activity relationships represents an active frontier in BPC-157 cardiovascular research research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to BPC-157 cardiovascular research. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
These findings demonstrate the multifaceted nature of BPC-157 cardiovascular research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Galluzzi et al., 2017, establishing critical parameters for understanding these mechanisms.
Molecular Mechanisms and Cellular Signaling
Understanding molecular mechanisms and cellular signaling is fundamental to comprehensive BPC-157 cardiovascular research investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Studies examining BPC-157 cardiovascular research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
Published studies frequently employ high-purity research compounds. BPC-157 from Proxiva Labs meet stringent purity requirements, verified by independent testing.
The cumulative evidence provides a solid foundation for continued BPC-157 cardiovascular research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Goldstein et al., 2010, establishing critical parameters for understanding these mechanisms.
Biomarker Analysis and Outcome Measures
Investigation of biomarker analysis and outcome measures represents an active frontier in BPC-157 cardiovascular research research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Longitudinal research tracking BPC-157 cardiovascular research effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
Published studies frequently employ high-purity research compounds. BPC-157 from Proxiva Labs meet stringent purity requirements, verified by independent testing.
The cumulative evidence provides a solid foundation for continued BPC-157 cardiovascular research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Naidu et al., 2017, establishing critical parameters for understanding these mechanisms.
Genomic and Transcriptomic Evidence
Research into genomic and transcriptomic evidence has generated substantial evidence illuminating how BPC-157 cardiovascular research interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Longitudinal research tracking BPC-157 cardiovascular research effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
For laboratory work, BPC-157 are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Rajman et al., 2018, establishing critical parameters for understanding these mechanisms.
Combination Research and Synergistic Effects
Investigation of combination research and synergistic effects represents an active frontier in BPC-157 cardiovascular research research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Studies examining BPC-157 cardiovascular research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
For laboratory work, BPC-157 are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
These findings demonstrate the multifaceted nature of BPC-157 cardiovascular research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Campisi et al., 2019, establishing critical parameters for understanding these mechanisms.
Dose-Response Data and Optimal Concentrations
Research into dose-response data and optimal concentrations has generated substantial evidence illuminating how BPC-157 cardiovascular research interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Studies examining BPC-157 cardiovascular research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
Published studies frequently employ high-purity research compounds. BPC-157 from Proxiva Labs meet stringent purity requirements, verified by independent testing.
These findings demonstrate the multifaceted nature of BPC-157 cardiovascular research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Deacon et al., 2020, establishing critical parameters for understanding these mechanisms.
Safety and Tolerability in Published Research
Investigation of safety and tolerability in published research represents an active frontier in BPC-157 cardiovascular research research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Quantitative analysis of BPC-157 cardiovascular research in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The cumulative evidence provides a solid foundation for continued BPC-157 cardiovascular research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Coskun et al., 2022, establishing critical parameters for understanding these mechanisms.
Pharmacokinetic Profile and Bioavailability
Investigation of pharmacokinetic profile and bioavailability represents an active frontier in BPC-157 cardiovascular research research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Studies examining BPC-157 cardiovascular research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The cumulative evidence provides a solid foundation for continued BPC-157 cardiovascular research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Lopez-Otin et al., 2013, establishing critical parameters for understanding these mechanisms.
Frequently Asked Questions
Is this research clinically relevant?
While most BPC-157 cardiovascular research research is preclinical, translational potential is considerable. Related compounds have progressed through clinical trials. All Proxiva Labs peptides are strictly for laboratory research, not human consumption.
How long until results are visible?
Timelines vary by model and endpoint. In vitro changes appear within hours to days; in vivo outcomes require days to weeks. Chronic studies may extend months. Pilot studies to establish optimal timepoints are strongly recommended.
What equipment is needed?
Standard molecular biology equipment including analytical balances, calibrated micropipettes, HPLC systems, and appropriate cell culture or animal facilities. Specialized endpoints may require plate readers, flow cytometers, or mass spectrometers.
How should researchers study BPC-157 cardiovascular research?
Begin with thorough literature review to identify current protocols and validated outcomes. Standard approaches include in vitro cell culture, ex vivo tissue models, and in vivo animal studies with institutional ethical approval. Proper controls, randomization, and blinding are essential.
What mistakes should researchers avoid?
Common pitfalls: using compounds below 95% purity, failing to verify identity via mass spectrometry, inadequate sample sizes, and improper storage causing degradation. Always source from suppliers with verified purity documentation.
What is BPC-157 cardiovascular research?
Bpc-157 cardiovascular research encompasses a specific area of peptide science attracting significant research interest due to potential applications in biological research. Published studies document multiple evidence lines supporting its scientific significance, from molecular mechanisms to translational applications in preclinical models.
What does the research say about BPC-157 cardiovascular research?
Peer-reviewed literature on BPC-157 cardiovascular research spans multiple journals, providing growing evidence supporting continued investigation. Key findings include dose-dependent effects in preclinical models, characterized pharmacokinetic profiles, and favorable safety data within studied concentrations.
Related Research Resources
Explore more from Proxiva Labs:
- Ipamorelin — a selective growth hormone secretagogue studied for GH pulse dynamics
- Glow — a proprietary peptide blend studied for skin health and rejuvenation
- KPV — an alpha-MSH fragment studied for anti-inflammatory and antimicrobial effects
- CJC-1295 No DAC — a growth hormone releasing hormone analog studied for sustained GH elevation
- Tirzepatide — a dual GIP/GLP-1 receptor agonist with emerging metabolic research applications
- Browse All Research Guides
- Shop All Peptides
- Third-Party Test Results
Shop Research Peptides at Proxiva Labs
USA-Made • ?98% HPLC Purity • Third-Party Tested • Free Shipping $150+ • COA Included
a gastric pentadecapeptide studied for tissue repair and wound healing
an amino acid derivative studied for fatty acid transport and energy metabolism
a copper-binding tripeptide studied for skin remodeling and gene expression modu
a synthetic melanocortin peptide studied for melanogenesis and photoprotection
a mitochondrial-derived peptide studied for metabolic regulation and exercise mi
a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors
a modified GH fragment studied for lipolytic activity and fat metabolism